CBD has moved from niche wellness to a mainstream consumer industry, reshaping how people think about anxiety and stress. Demand concentrates among women (62% of U.S. CBD consumers) and millennials make up 54% of global buyers, but quality remains a major question. Studies suggest 70% of CBD products fail potency tests, even as clinical research expands—150+ active trials as of 2023. This page tracks market growth and the regulatory patchwork across the U.S. and Europe.
Key Takeaways
- 45% of U.S. adults have tried CBD products as of 2023.
- Women represent 62% of CBD consumers in the U.S.
- Millennials (25-40) make up 54% of CBD buyers globally.
- 70% of CBD products fail potency tests per studies.
- Clinical trials on CBD: 150+ active as of 2023.
- CBD reduces anxiety in 79% of users per meta-analysis.
- The global CBD market was valued at USD 7.7 billion in 2023 and is expected to grow to USD 47.22 billion by 2030 at a CAGR of 29.2%.
- U.S. CBD sales reached $5.3 billion in 2022, up 15% from the previous year.
- The hemp-derived CBD market in North America is projected to grow at a CAGR of 25.4% from 2023 to 2030.
- CBD Oils represent 40% of U.S. sales volume in 2023.
- Gummies/edibles captured 28% market share in 2023.
- CBD beverages sales reached $118 million in U.S. 2023.
- 2018 Farm Bill enabled hemp-derived CBD federally.
- FDA approved Epidiolex (CBD) for epilepsy in 2018.
- 38 U.S. states have CBD-specific regulations as of 2023.
In 2023, CBD usage and approvals grew fast despite widespread potency failures, with anxiety relief driving demand.
Related reading
01 · Category
Consumer Trends30 stats
01
45% of U.S. adults have tried CBD products as of 2023.
02
Women represent 62% of CBD consumers in the U.S.
03
Millennials (25-40) make up 54% of CBD buyers globally.
04
38% of CBD users cite anxiety relief as primary reason.
05
Repeat CBD purchasers: 67% in U.S. market 2023.
06
Urban consumers 2x more likely to use CBD than rural.
07
52% of CBD users are college-educated.
08
Average age of CBD consumer: 37 years old in 2023.
09
29% of U.S. parents have given CBD to children.
10
Hispanic consumers CBD adoption rate: 41% in U.S.
11
71% of CBD users prefer full-spectrum products.
12
Daily CBD use among consumers: 23% in Europe.
13
Income level: 48% of CBD buyers earn >$75k/year.
14
55% of Gen Z aware of CBD benefits.
15
CBD use for sleep: 44% of consumers primary use.
16
36% of athletes report using CBD regularly.
17
Female CBD consumers aged 25-34: 28% of total market.
18
62% of CBD users learn from social media.
19
Chronic pain drives 51% of CBD purchases.
20
19% of seniors (65+) tried CBD in 2023.
21
LGBTQ+ community CBD usage: 53% adoption rate.
22
40% prefer organic CBD, per consumer polls.
23
Weekly CBD use: 31% among U.S. consumers.
24
27% of consumers mix CBD with THC products.
25
Pet owners CBD use for pets: 34%.
26
Brand loyalty in CBD: 58% stick to one brand.
27
Oils/tinctures preferred by 49% of consumers.
28
CBD gummies sales driven by 60% female buyers.
29
33% of consumers influenced by celebrity endorsements.
30
Topicals used by 42% for skin issues.
Interpretation
Consumer Trends Interpretation
In consumer trends, CBD is becoming a mainstream wellness habit with 45% of U.S. adults trying it in 2023 and strong repeat purchasing of 67%, showing that demand is shifting beyond first-time experimentation.
02 · Category
Health Claims And Research22 stats
01
70% of CBD products fail potency tests per studies.
02
Clinical trials on CBD: 150+ active as of 2023.
03
CBD reduces anxiety in 79% of users per meta-analysis.
04
Epidiolex efficacy: 40% seizure reduction in trials.
05
CBD for chronic pain: 30mg dose effective in 60%.
06
Sleep improvement with CBD: 66% reported better sleep.
07
Anti-inflammatory effects confirmed in 25 animal studies.
08
CBD acne treatment: Reduces sebum 25% in vitro.
09
PTSD symptom reduction: 49% with CBD therapy.
10
Neuroprotective potential in Alzheimer's models: 45%.
11
CBD addiction treatment: Reduces cue-induced craving 40%.
12
Epilepsy patients on CBD: 50% responder rate.
13
Side effects mild: 13% report drowsiness.
14
CBD schizophrenia adjunct: Improves symptoms 29%.
15
Athletic recovery: Muscle soreness down 20-30%.
16
COVID-19 cytokine storm: CBD inhibits 50% in models.
17
92% of CBD claims unproven per FDA review.
18
Human bioavailability oral CBD: 13-19%.
19
Anti-nausea: Superior to placebo in 68% chemo patients.
20
Diabetes neuropathy pain relief: 60% improvement.
21
250+ preclinical studies on CBD anti-cancer effects.
22
Pet anxiety reduction: 74% efficacy in dogs.
Interpretation
Health Claims And Research Interpretation
Across health claims and research, evidence is promising but inconsistent, with 70% of CBD products failing potency tests even as studies report benefits such as 79% anxiety reduction and 66% sleep improvement and clinical activity topping 150 trials by 2023.
03 · Category
Market Growth And Size30 stats
01
The global CBD market was valued at USD 7.7 billion in 2023 and is expected to grow to USD 47.22 billion by 2030 at a CAGR of 29.2%.
02
U.S. CBD sales reached $5.3 billion in 2022, up 15% from the previous year.
03
The hemp-derived CBD market in North America is projected to grow at a CAGR of 25.4% from 2023 to 2030.
04
Europe's CBD market size was estimated at EUR 1.2 billion in 2022, with a forecasted CAGR of 22% through 2028.
05
Online CBD sales accounted for 68% of total U.S. CBD market revenue in 2023.
06
The CBD-infused beverage market is expected to reach $1.6 billion by 2025 globally.
07
CBD pet products market grew to $327 million in U.S. sales in 2022.
08
Global CBD cosmetics market valued at $1.1 billion in 2023, projected CAGR 31.5% to 2030.
09
U.S. CBD market projected to hit $16 billion by 2025.
10
Asia-Pacific CBD market expected to grow at CAGR 28.7% from 2023-2030 due to legalization trends.
11
CBD edibles segment held 35% market share in 2023 globally.
12
U.S. retail CBD sales increased 101% year-over-year in Q1 2023.
13
Global CBD oil market size was $4.9 billion in 2022, CAGR 23.6% to 2030.
14
Hemp CBD market in U.S. saw 20% growth in 2023 despite economic challenges.
15
Projected global CBD market revenue: $22 billion by 2025.
16
Latin America CBD market to grow at 30.2% CAGR through 2028.
17
U.S. CBD vape market declined 25% in 2022 but stabilizing in 2023.
18
CBD wellness products market reached $2.5 billion globally in 2023.
19
Canada CBD market valued at CAD 1.1 billion in 2023, CAGR 26% forecast.
20
Global CBD topicals market to reach $5.4 billion by 2030.
21
U.S. CBD market share of hemp industry: 45% in 2023.
22
International CBD exports from U.S. grew 35% in 2022.
23
CBD sleep aids segment projected CAGR 32% to 2028.
24
Global CBD market penetration in nutraceuticals: 12% in 2023.
25
U.S. CBD sales via convenience stores up 45% in 2023.
26
Europe CBD food market CAGR 24.8% from 2023-2030.
27
Global CBD e-commerce sales hit $3.2 billion in 2023.
28
U.S. CBD market CAGR post-2018 Farm Bill: 28% annually.
29
Projected 2030 global CBD market: $61 billion.
30
CBD beauty market in Asia grew 40% YoY in 2023.
Interpretation
Market Growth And Size Interpretation
The CBD market’s rapid expansion is clear from the jump from USD 7.7 billion in 2023 to a projected USD 47.22 billion by 2030 at a 29.2% CAGR, reinforcing that market growth and size are accelerating across major regions and channels.
More related reading
report visual · Projection
Global CBD market size growth (2023–2030)
The global CBD market shows a consistent upward trend in size from 2023 through 2030, with the projected 2030 market leading the time series and indicating sustained growth across
7.7 USD (billions)
Start
+29.57%
CAGR · 7y
47.2 USD (billions)
Projected
20232030
source-verifiedfortunebusinessinsights.com2030
04 · Category
Product And Sales Data25 stats
01
CBD Oils represent 40% of U.S. sales volume in 2023.
02
Gummies/edibles captured 28% market share in 2023.
03
CBD beverages sales reached $118 million in U.S. 2023.
04
Topicals/beauty products: 22% of global CBD revenue.
05
Pet CBD products sales: $594 million projected 2024.
06
Vapes declined to 8% market share in U.S. 2023.
07
Capsules/pills: 12% of sales, growing 18% YoY.
08
Food & beverage CBD infusions: $276 million U.S. 2022.
09
Full-spectrum CBD products 55% of sales.
10
Broad-spectrum CBD rising to 25% share.
11
Isolate CBD products: 20% market share declining.
12
Online sales channel: 65% of total CBD revenue.
13
Brick-and-mortar CBD sales: 35%, led by smoke shops.
14
Average CBD oil bottle price: $49.99in 2023.
15
Gummies average price per pack: $24.50.
16
CBD flower sales surged 40% in legal states.
17
Wellness supplements with CBD: $1.2 billion sales.
18
Cosmetics/skincare CBD: 31% CAGR segment.
19
Sleep-specific CBD products: $450 million U.S.
20
Pain relief topicals: 18% of topical sales.
21
Private label CBD brands: 15% market penetration.
22
Hemp seed oil vs CBD oil confusion affects 22% sales.
23
Subscription model CBD sales: 12% of online revenue.
24
International CBD product exports: $250 million U.S.
25
Delta-8 THC/CBD hybrid products: 10% sales growth.
Interpretation
Product And Sales Data Interpretation
In product and sales data, CBD oils led US demand with 40% of 2023 volume while gummies and edibles held a strong 28% share and vapes slipped to just 8%, showing a clear shift toward ingestible and oil formats.
05 · Category
Regulatory And Legal Aspects21 stats
01
2018 Farm Bill enabled hemp-derived CBD federally.
02
FDA approved Epidiolex (CBD) for epilepsy in 2018.
03
38 U.S. states have CBD-specific regulations as of 2023.
04
EU Novel Food status requires CBD authorization since 2019.
05
DEA rescheduled hemp <0.3% THC as non-controlled 2020.
06
15 countries in Europe allow CBD sales medically.
07
USDA hemp production acres: 440,000 in 2022.
08
FDA warning letters to CBD firms: 120+ since 2019.
09
UK caps CBD THC at 0.2% for legal sale.
10
Brazil legalized CBD imports via Anvisa in 2015.
11
Australia TGA lists low-dose CBD as Schedule 3.
12
Canada allows CBD in non-health products since 2018.
13
U.S. states banning CBD sales: 4 as of 2023.
14
FTC CBD advertising enforcement cases: 25 in 2022.
15
Switzerland permits CBD <1% THC freely.
16
Mexico decriminalized CBD possession up to 5g.
17
FDA CBD in food/drinks: Not GRAS status.
18
Hemp testing labs accredited: 150+ in U.S.
19
EU CBD flower ban in France/Germany upheld 2023.
20
U.S. hemp licensing states: 50 all legalized.
21
WHO pre-review: CBD not scheduled internationally.
Interpretation
Regulatory And Legal Aspects Interpretation
Since the 2018 Farm Bill and FDA’s approval of Epidiolex helped legitimize CBD, the regulatory landscape has rapidly expanded, with 38 U.S. states adopting CBD-specific rules by 2023 and the EU requiring Novel Food authorization for CBD since 2019.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Cbd Industry Statistics. Gitnux. https://gitnux.org/cbd-industry-statistics
MLA
Elena Vasquez. "Cbd Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cbd-industry-statistics.
Chicago
Elena Vasquez. 2026. "Cbd Industry Statistics." Gitnux. https://gitnux.org/cbd-industry-statistics.
Sources & references
1 datasets cited across this report · attribution is report-level